Meningococcal Vaccines

These are shots you can get to protect yourself from Neisseria meningitidis bacteria. They help your body build immunity so you don't get sick if you are exposed to the bacteria. There are different types of meningococcal vaccines available.

Brand names:Menactra, Menomune, Menveo, Bexsero, Trumenba
Medication

What people taking Meningococcal Vaccines report

Every report comes from a Lived member, sent anonymously.

Have you tried Meningococcal Vaccines for Hereditary Complement Deficiency Diseases?

NameHow it went

About Meningococcal Vaccines

What It's For

Meningococcal vaccines protect against meningococcal disease, a group of serious infections caused by the bacterium Neisseria meningitidis. The two most common forms are meningitis, an infection of the lining around the brain and spinal cord, and a bloodstream infection (sepsis). The disease is uncommon in the United States, but it develops quickly, often in people who were healthy. Even with treatment, about 15 in 100 people who get it die, and 10 to 20 in 100 survivors are left with lasting problems such as hearing loss, brain injury or loss of fingers, toes or limbs. The bacteria come in several types, called serogroups, and most US cases are caused by groups B, C, W and Y. No single older vaccine covers them all, so there are three kinds. MenACWY vaccines protect against groups A, C, W and Y: Menveo is approved from 2 months through 55 years of age, and MenQuadfi from 6 weeks of age onward. MenB vaccines, Bexsero and Trumenba, protect only against group B and are approved for ages 10 through 25. Two newer combination vaccines, Penbraya and Penmenvy, cover all five groups (A, B, C, W and Y) in one shot for ages 10 through 25, and can be used when both kinds are due at the same visit. Menactra, a former MenACWY brand, was replaced by MenQuadfi in 2022, and the older Menomune vaccine is no longer available in the US. In the US, every adolescent is advised to get a MenACWY vaccine. For healthy teens and young adults aged 16 to 23, MenB vaccination is a choice made together with a clinician, ideally at 16 to 18. Both kinds are recommended for people at higher risk, including people whose spleen has been removed or does not work properly (as in sickle cell disease), people with certain rare inherited immune problems called complement deficiencies, and people taking complement inhibitor medicines such as eculizumab (Soliris) or ravulizumab (Ultomiris). MenACWY is also recommended for people with HIV (human immunodeficiency virus), first-year college students living in residence halls who are not fully vaccinated, military recruits, travelers to parts of the world where the disease is common, and people caught up in an outbreak.

How It Works

A vaccine teaches the immune system to recognize a germ before a real infection. Meningococcal bacteria are wrapped in a sugar coating, called a capsule, and the coating differs from one serogroup to the next. MenACWY vaccines contain pieces of the A, C, W and Y coatings attached to a carrier protein, which is why they are called conjugate vaccines. The body responds by making antibodies that latch onto those coatings and, together with a part of the immune system called complement, kill the bacteria. MenB vaccines work differently: instead of the coating, they use proteins from the surface of the group B bacteria. How well they protect against a particular group B strain depends on how closely that strain's surface proteins match the ones in the vaccine, so they may not cover every strain. Because killing the bacteria depends on complement, people with complement deficiencies or who take complement inhibitors can still get meningococcal disease even after making antibodies. Protection also fades with time. Antibodies after a first MenACWY dose decline over 3 to 5 years, which is why a booster at 16 carries protection through the late teens, when risk rises again after early childhood. Protection from MenB fades faster, within 1 to 2 years, and MenB vaccines do not seem to stop the bacteria from living harmlessly in the nose and throat, so they protect the person vaccinated but are unlikely to protect the people around them.

Dosage & Administration

All meningococcal vaccines are given as an injection into a muscle, usually the upper arm, and can generally be given at the same visit as other vaccines. For healthy adolescents, the MenACWY schedule is one dose at age 11 or 12 and a booster at 16. Someone whose first dose comes at 13 to 15 gets the booster at 16 to 18; someone first vaccinated at 16 or older usually needs no booster unless their risk rises. The MenACWY brands can be swapped between doses. Babies and young children at higher risk receive a series of two to four doses, depending on the age they start, and people who stay at higher risk get boosters at regular intervals. MenB vaccines are given as two doses six months apart for most healthy teens and young adults. People at higher risk, or anyone in a group B outbreak, receive three doses (at the start, one to two months later and six months later), plus later boosters if the risk continues. The two MenB brands are not interchangeable, so every dose in a series must be the same product. The same rule applies after a combination vaccine: any further MenB doses should come from the same manufacturer. The combination vaccines themselves are given as two doses six months apart. For anyone starting a complement inhibitor such as eculizumab, meningococcal vaccination should be completed or updated at least two weeks before the first dose, unless delaying treatment would be riskier.

Side Effects

Soreness, redness or swelling where the shot was given are the most common effects, along with headache, tiredness and muscle aches. With MenACWY vaccines these are usually mild and settle within about three days. MenB and combination vaccines cause more noticeable reactions: in studies, more than 8 in 10 teens and young adults had a sore arm afterward, about half or more felt tired, and some had fever, chills or nausea. Babies may be fussy or sleepy for a short time after a dose. Some people faint after an injection, so clinics take steps to prevent injury from a fall. Tell the person giving the shot about any dizziness, changes in vision or ringing in the ears. Severe allergic reactions are very rare. Signs include hives, swelling of the face or throat, trouble breathing, a fast heartbeat, dizziness or weakness, and they can start after leaving the clinic. If these appear, call 911.

Interactions & Warnings

Anyone who had a severe allergic reaction to an earlier dose of a meningococcal vaccine, or to one of its ingredients, should not receive that vaccine. For Menveo this also includes a severe allergy to any vaccine containing diphtheria toxoid. A person with a history of Guillain-Barré syndrome, a rare nerve disorder that causes weakness, should talk this through first: the condition was reported after an older meningococcal vaccine, although later studies did not find a higher risk. People with a weakened immune system, including those on immune-suppressing medicines, may not respond as strongly to the vaccine. People with complement deficiencies or on complement inhibitors such as eculizumab (Soliris) remain at much higher risk even after vaccination, and their clinician may also prescribe antibiotics for protection while treatment continues. No meningococcal vaccine covers every strain, and MenACWY does not protect against group B (nor MenB against the other groups). Fever with a severe headache and stiff neck, confusion, or a dark purple rash can signal meningococcal disease and needs emergency medical care right away, especially for someone on a complement inhibitor. During pregnancy or breastfeeding, MenACWY can be given when it is needed. MenB vaccination is usually postponed during pregnancy unless the person is at increased risk. People with a minor illness such as a cold can be vaccinated, while someone moderately or severely ill usually waits until they recover.

What to Expect

The visit itself is quick, and any soreness or tiredness usually fades within a few days. Keeping a record of which vaccine was given, and when, matters more than with many shots, because the booster timing and the rule of finishing a MenB series with the same brand both depend on it. For most teens, the MenACWY booster at 16 completes the routine schedule. The decision about MenB for a healthy 16 to 23 year old weighs a rare but devastating infection against short-term protection. From 2015 to 2018 there were about 34 group B cases a year among people that age in the whole US. Risk is higher in college students, especially first-year students at four-year universities, those in on-campus housing and members of sororities and fraternities. People at ongoing high risk, such as those without a working spleen or on complement inhibitors, should expect repeated boosters over the years rather than a single series, and should still treat possible symptoms of meningococcal disease as urgent.

Questions to Ask Your Doctor

  1. 1.Which meningococcal vaccines does my child or do I need, and are any doses or boosters still missing?
  2. 2.Given our plans for college, travel or living arrangements, would MenB vaccination be worthwhile, and when is the best time?
  3. 3.Would a combination vaccine reduce the number of shots, and which brand should we stay with for later MenB doses?
  4. 4.Because of my medical condition or treatment, how often will I need boosters, and do I also need preventive antibiotics?

Last reviewed • Oct 2026

Educational content, not medical advice.